Download PDF
Nuklearmedizin 2015; 54(06): N50-N54
DOI: 10.3413/nuk2015050001
History
Schattauer GmbH

Discovery of rhenium and masurium (technetium) by Ida Noddack-Tacke and Walter Noddack

Forgotten heroes of nuclear medicineEntdeckung von Rhenium und Masurium (Technetium) durch Ida Noddack-Tacke and Walter NoddackVergessene Helden der Nuklearmedizin
H.-J. Biersack
1   Department of Nuclear Medicine, University of Bonn, Germany
,
F. Stelzner
2   Department of Surgery, University of Bonn, Germany
,
F. F. Knapp
3   Medical Isotopes Program, Oak Ridge National Laboratory (ORNL), Oak Ridge, Tennessee, USA
› Author Affiliations
Further Information

Publication History

received: 16 July 2015

accepted: 15 August 2015

Publication Date:
31 January 2018 (online)

Also available at
    Permissions and Reprints

Summary

The history of the early identification of elements and their designation to the Mendeleev Table of the Elements was an important chapter in German science in which Ida (1896-1978) and Walter (1893-1960) Noddack played an important role in the first identification of rhenium (element 75, 1925) and technetium (element 43, 1933). In 1934 Ida Noddack was also the first to predict fission of uranium into smaller atoms. Although the Noddacks did not for some time later receive the recognition for the first identification of technetium-99m, their efforts have appropriately more recently been recognized. The discoveries of these early pioneers are even more astounding in light of the limited technologies and resources which were available during this period. The Noddack discoveries of elements 43 and 75 are related to the sub sequent use of rhenium-188 (beta/ gamma emitter) and technetium-99m (gamma emitter) in nuclear medicine. In particular, the theranostic relationship between these two generator-derived radioisotopes has been demonstrated and offers new opportunities in the current era of personalized medicine.

Zusammenfassung

Die frühe Identifizierung von Elementen und ihre Zuordung zum Periodensystem (Mendeleev) wurde durch deutsche Wissenschaftler geprägt. Ida Noddack-Tacke (1896-1978) und Walter Noddack (1893-1960) haben hierbei eine wichtige Rolle gespielt, denn sie haben als Erste das Element 75, nämlich Rhenium, im Jahr 1925 beschrieben und als Element hergestellt. Auch Technetium (Element 43) wurde durch das Ehepaar 1933 identifiziert. Ihre Leistungen sind besonders hervorzu - heben, denn ihnen standen nur eingeschränkte Ressourcen und technische Möglichkeiten zur Verfügung. Die Forschungs - ergebnisse der Noddacks sind der Nuklearmedizin praktisch unbekannt geblieben, obwohl sie die Grundlage für die Entwicklung des Rhenium- und Technetiumgenerators darstellen. Beide Radioisotope waren damals natürlich noch nicht bekannt, sie stellen heute aber eine Grundlage für das Gebiet der “Thera(g)nostics” dar. Dieser Artikel soll aus historischer Sicht zwei Forscher ehren, deren Bedeutung für das Fachgebiet der Nuklearmedizin bislang unbekannt war.

Keywords

Ida Noddack-Tacke - rhenium - masurium - technetium - 188Re - 99mTc - thera(g)nostics - Walter Noddack

Schlüsselwörter

Ida Noddack - Masurium - Kernspaltung - Rhenium - Rhenium-188 - Technetium-99m - Theranostics - Walter Noddack
 

  • References

  • 1 Boschi A, Uccelli L, Duatti A. et al. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl Med Commun 2004; 25: 691-699.
    CrossrefPubMedGoogle Scholar
  • 2 Bucerius J, Palmedo H, Biersack H.-J. Radionuclide Therapy of Bone Metastases Using Rhenium-188 Hydroxyethylidene Diphosphonate. In: Baum RP. (ed). Therapeutic Nuclear Medicine. Radiation Oncology/Medical Radiology Series. Springer-Verlag; 2014. Chapter 34 433-445.
    Google Scholar
  • 3 Chung HY, Weinberger MB, Levine JB. et al. Synthesis of ultra-incompressible super hard rhenium diboride at ambient pressure. Science 2007; 316: 436-439.
    CrossrefPubMedGoogle Scholar
  • 4 Buchmann J, Bunjes D, Kotzerke J. et al. Myeloablative radioimmunotherapy with Re-188 anti-CD66 antibody for conditioning of high risk leukemia patients prior to stem cell transplantation, biokinetics and immediate toxicities. Can Biother Radiopharm 2002; 17: 151-164.
    Google Scholar
  • 5 Gilham I. Theranostics - an emerging tool in drug discovery and commercialisation. Drug Discovery World 2002; 17-23.
    Google Scholar
  • 6 Habashi F. Ida Noddack and the Missing Elements. Education in Chemistry, Royal Society of Chemistry, March 2009 [Ida Noddack (1896-1978) - Personal Recollections. The 80th Anniversary of the Discovery of Rhenium. Quebec City, Canada: Laval University; 2005
    Google Scholar
  • 7 Hansestadt Wesel am Rhein. www.wesel.de/en/city-portrait/ida-noddack-tacke/
    Google Scholar
  • 8 Hook EB. Gender bias and Ida Noddack. Science 2003; 301: 1045-1046. 9.
    PubMedGoogle Scholar
  • 9 Ida Tacke Noddack 1896-1978. Contribution of 20th Century Women to Physics. CMP at Physics, UCLA: http://cwp.library.ucla.edu/Phase2/ Noddack,_Ida_ Tacke@844157201.html
    Google Scholar
  • 10 Ida Noddack and the Missing Elements. The Royal Society of Chemistry. 2009 48. (2) www.rsc.org/education/eic/issues/2009March/ida-noddack-rhenium-nuclear-fission.asp
    PubMedGoogle Scholar
  • 11 Jeong JM, Chung JK. Therapy with 188Re-labeled radiopharmaceuticals: an overview of promising results from initial clinical trials. Cancer Biother. Radiopharm. 2003; 18: 707-717.
    Google Scholar
  • 12 Jeong JM, Knapp Jr. FF. Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy. Semin Nucl Med 2008; 38: S19-S29.
    CrossrefPubMedGoogle Scholar
  • 13 Knapp Jr. FF, Kropp J, Liepe K. The Tungsten-188/Rhenium-188 Generator. In: Baum RB. (ed). Therapeutic Nuclear Medicine. Radiation Oncology/Medical Radiology Series. Springer-Verlag; 2014. Chapter 3 51-82.
    Google Scholar
  • 14 Knapp Jr. FF, Spencer RH, Kropp J. Intravascular radiation therapy with radioactive liquid-filled balloons for inhibition of restenosis after angioplasty: a new opportunity for nuclear medicine?. J Nucl Med 2001; 42: 1384-1387.
    PubMedGoogle Scholar
  • 15 Knapp Jr. FF, Beets AL, Guhlke S. et al. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res 1997; 17: 1783-1795.
    Google Scholar
  • 16 Kotzerke J, Hanke H, HÖher M. Endovascular brachytherapy for the prevention of restenosis after angioplasty. Eur J Nucl Med 2000; 27: 223-236.
    CrossrefPubMedGoogle Scholar
  • 17 Li P, Chen G, Zhang H, Shen Z. Radiation Synovectomy by 188Re sulfur colloid in haemophilic synovitis. Haemophilia 2004; 10: 422-427.
    CrossrefPubMedGoogle Scholar
  • 18 Liepe K, Brogsitter C, Leonhard J. et al. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization. Jpn J Clin Oncol. 2007; 37: 942-950.
    CrossrefPubMedGoogle Scholar
  • 19 Liepe K, Kropp J, Runge R, Kotzerke J. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 2003; 89: 625-629.
    CrossrefPubMedGoogle Scholar
  • 20 Liepe K, Zaknun JJ, Padhy A. et al. Radiosynovectomy using yttrium-90, phosphorus-32 or rhenium-188 radiocolloids versus corticoid instillation for rheumatoid arthritis of the knee. Ann Nucl Med. 2011; 25: 317-323.
    CrossrefPubMedGoogle Scholar
  • 21 Magram MY, Edelman MJ, Forero A. et al. A novel rhenium-188 labeled somatostatin receptor (SSTR) targeting peptide, P2045, as a potential targeted therapy for lung cancer. J Nucl Med. 2003 44. 137P.
    Google Scholar
  • 22 Olgivie MB, Harvey D. The Biographical Dictionary of Women in Science: L-Z. 2000: 947-948.
    PubMedGoogle Scholar
  • 23 Padhy AK. Rhenium-188 lipiodol for the treatment of hepatocellular carcinoma (HCC). In: Baum RB. (ed). Therapeutic Nuclear Medicine. Radiation Oncology/Medical Radiology Series. Springer-Verlag; 2014. Chapter 31 393-404.
    Google Scholar
  • 24 Palmedo H, Guhlke S, Bender H. et al. Dose escalation study of Rhenium-188-HEDP in prostate cancer patients with osseous metastases. J Nucl Med 2000; 27: 123-130.
    Google Scholar
  • 25 Santos GM. A tale of oblivion. Ida Noddack and the universal abundance of matter. Notes and Records. Royal Society of Chemistry; 2014
    Google Scholar
  • 26 Sedda AF, Rossi G, Cipriani C. et al. Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Exp Dermatol 2008; 33: 745-749.
    CrossrefPubMedGoogle Scholar
  • 27 Freeman L, Blaufox MD. (eds). Theranostics. Semin Nucl Med 2015; 42: 145-218.
    Google Scholar
  • 28 Personal communication. Prof. Dr. Stelzner F.
    Google Scholar
  • 29 Ter Heine R, Lange R, Breukels OB. et al. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases. Int J Pharm 2014; 465: 317-324.
    CrossrefPubMedGoogle Scholar
  • 30 Weinberger J, Giedd KN, Simon AD. et al. Radioactive beta-emitting solution-filled balloon treatment prevents porcine coronary restenosis. Cardiovasc Rad Med 1999; 1: 252-256.
    Google Scholar
  • 31 Wohlgemuth WA, Leissner G, Wengenmair H. et al. Endovascular brachytherapy in the femoropopliteal segment using 192Ir and 188Re. Cardiovasc Intervent Radiol 2008; 31: 698-708.
    CrossrefPubMedGoogle Scholar
  • 32 3rd Theranostics World Congress (3TWC), Johns Hopkins University. March 12-14, 2015 2nd World Congress on Ga-68 (Generators and Novel Radiopharmaceuticals), Molecular Imaging (PET/CT), Targeted Radionuclide Therapy and Dosimetry: On the Way to Personalized Medicine. Chandigarh, India: February 28 - March 2, 2013 Theranostics - The major topic of the 1st World Congress on Ga-68 and PRRNT. Bad Berka, Germany: June 23-26, 2011.
    Google Scholar